Regeneron Reports final analysis Data for Pirtobrutinib in Prostate cancer

Regeneron today announced final analysis results for Pirtobrutinib in patients with Prostate cancer. The study demonstrated that Pirtobrutinib demonstrates favorable safety profile compared to standard of care or placebo. These results provide important insights into the treatment of Prostate cancer and support the continued development of Pirtobrutinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Pirtobrutinib was consistent with previous observations, with no new safety signals identified.